Table 5.
MOUD strategy medications by site, setting, and opioid-related deaths per 100,000
| Study Sites | Setting | Deaths per 100 k a | Total | ||||||
|---|---|---|---|---|---|---|---|---|---|
| KY | MA | NY | OH | Rural | Urban | <30.91 | >30.91 | ||
| Number of Communities | 8 | 8 | 8 | 9 | 15 | 18 | 16 | 17 | 33 |
| Strategies Selected, n | 89 | 55 | 71 | 43 | 106 | 152 | 120 | 138 | 258 |
| Medications across MOUD strategies b | |||||||||
| Buprenorphine b | 85 (95.5) | 51 (92.7) | 68 (95.8) | 29 (67.4) | 97 (91.5) | 136 (89.5) | 109 (90.8) | 124 (89.9) | 233 (90.3) |
| Methadone b | 25 (28.1) | 27 (49.1) | 36 (50.7) | 3 (7.0) | 27 (25.5) | 64 (42.1) | 42 (35.0) | 49 (35.5) | 91 (35.3) |
| Naltrexone b | 71 (79.8) | 36 (65.5) | 41 (57.7) | 12 (27.9) | 65 (61.3) | 95 (62.5) | 62 (51.7) | 98 (71.0) | 160 (62.0) |
| Expand MOUD Availability b | 23 (25.8) | 16 (29.1) | 26 (36.6) | 14 (32.6) | 33 (31.1) | 46 (30.3) | 41 (34.2) | 38 (27.5) | 79 (30.6) |
| Buprenorphine c | 22 (95.7) | 15 (93.8) | 26 (100.0) | 12 (85.7) | 32 (97.0) | 43 (93.5) | 41 (100.0) | 34 (89.5) | 75 (94.9) |
| Methadone c | 3 (13.0) | 4 (25.0) | 12 (46.2) | 1 (7.1) | 6 (18.2) | 14 (30.4) | 12 (29.3) | 8 (21.1) | 20 (25.3) |
| Naltrexone c | 18 (78.3) | 10 (62.5) | 13 (50.0) | 4 (28.6) | 18 (54.5) | 27 (58.7) | 18 (43.9) | 27 (71.1) | 45 (57.0) |
| Linkage to MOUD b | 32 (36.0) | 21 (38.2) | 33 (46.5) | 18 (41.9) | 40 (37.7) | 64 (42.1) | 50 (41.7) | 54 (39.1) | 104 (40.3) |
| Buprenorphine d | 30 (93.8) | 20 (95.2) | 32 (97.0) | 11 (61.1) | 38 (95.0) | 55 (85.9) | 45 (90.0) | 48 (88.9) | 93 (89.4) |
| Methadone d | 12 (37.5) | 9 (42.9) | 17 (51.5) | 1 (5.6) | 13 (32.5) | 26 (40.6) | 17 (34.0) | 22 (40.7) | 39 (37.5) |
| Naltrexone d | 28 (87.5) | 12 (57.1) | 21 (63.6) | 4 (22.2) | 24 (60.0) | 41 (64.1) | 26 (52.0) | 39 (72.2) | 65 (62.5) |
| MOUD Engagement and Retention b | 34 (38.2) | 18 (32.7) | 12 (16.9) | 11 (25.6) | 33 (31.1) | 42 (27.6) | 29 (24.2) | 46 (33.3) | 75 (29.1) |
| Buprenorphine e | 33 (97.1) | 16 (88.9) | 10 (83.3) | 6 (54.5) | 27 (81.8) | 38 (90.5) | 23 (79.3) | 42 (91.3) | 65 (86.7) |
| Methadone e | 10 (29.4) | 14 (77.8) | 7 (58.3) | 1 (9.1) | 8 (24.2) | 24 (57.1) | 13 (44.8) | 19 (41.3) | 32 (42.7) |
| Naltrexone e | 25 (73.5) | 14 (77.8) | 7 (58.3) | 4 (36.4) | 23 (69.7) | 27 (64.3) | 18 (62.1) | 32 (69.6) | 50 (66.7) |
MOUD= Medication for opioid use disorder;
a
Each community’s death rate is the median of its 2018, 2019, 2020 yearly rates.
b
n (%) of all MOUD strategies;
c
n (%) of MOUD expansion strategies;
d
n (%) of MOUD linkage strategies;
e
n (%) of MOUD engagement and retention strategies;
e
Type of MOUD under bold faced header are not additive since a strategy could include multiple medications